Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone von ROSENBERG, Jonathan E, WEINBERG, Vivian K, KELLY, W. Kevin, MICHAELSON, Dror, HUSSAIN, Maha H, WILDING, George, GROSS, Mitchell, HUTCHEON, Douglass, SMALL, Eric J

Volltext

No More ‘Code Black’: Intervention to Improve Inpatient Flow at a Large Public Hospital von Coffey, Charles E., Carter, Valda, Wei, Eric, Hutcheon, Douglass, Gruen, John P., Anonas-Ternate, Annie, Sandoval, Rebecca, Marquez, Annie, Sarff, Laura, Spellberg, Brad

Volltext

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory p... von Ryan, Charles J, Stadler, Walter M, Roth, Bruce, Hutcheon, Douglass, Conry, Shauna, Puchalski, Thomas, Morris, Charles, Small, Eric J

Volltext

Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients von Rosenberg, Jonathan E., Weinberg, Vivian K., Kelly, W. Kevin, Michaelson, Dror, Hussain, Maha H., Wilding, George, Gross, Mitchell, Hutcheon, Douglass, Small, Eric J.

Volltext